Table 3.

Multivariate Cox regression analysis of prognostic factors in patients with antisynthetase syndrome.

VariableUnivariate AnalysisMultivariate Analysis
HR (95% CI)pHR (95% CI)p
Age, yrs1.075 (1.022–1.131)0.005
Sex0.388 (0.124–1.208)0.102
Duration0.986 (0.961–1.012)0.302
Muscle weakness0.678 (0.233–1.971)0.476
Myalgia0.366 (0.101–1.325)0.126
ILD21.7 (0.0–1495375.1)0.588
RP-ILD13.8 (4.459–42.945)< 0.0018.072 (1.280–50.923)0.026
Mechanic’s hands0.572 (0.178–1.837)0.348
Raynaud phenomenon1.375 (0.298–6.347)0.683
Gottron papules0.949 (0.329–2.737)0.923
Heliotrope rash0.959 (0.266–3.450)0.948
Arthritis/arthralgia0.775 (0.272–2.212)0.634
Dysphagia1.079 (0.240–4.841)0.921
Malignancy8.433 (2.462–28.879)0.00131.07 (2.182–442.36)0.011
Pericarditis2.762 (0.763–9.997)0.122
ANA1.187 (0.410–3.436)0.751
Anti-Ro522.487 (0.852–7.264)0.096
Anti-Ro600.350 (0.078–1.571)0.170
Anti-RNP0.045 (0.0–1713.71)0.564
With other CTD0.512 (0.112–2.333)0.387
Jo11.015 (0.343–2.998)0.979
PL71.755 (0.599–5.143)0.305
PL121.425 (0.317–6.403)0.644
EJ0.037 (0.000–16.479)0.290
Serum ferritin1.001 (1.000–1.001)0.0181.001 (1.000–1.002)0.042
CK0.999 (0.998–1.000)0.230
CRP0.458 (0.121–1.730)0.250
PFT findings
  DLCO, %0.941 (0.865–1.022)0.150
  FVC, %0.958 (0.910–1.009)0.103
  FEV1, %0.968 (0.923–1.015)0.176
  • ILD: interstitial lung disease; RP-ILD: rapidly progressive ILD; ANA: antinuclear antibodies; CTD: connective tissue disease; CK: creatine kinase; CRP: C-reactive protein; PFT: pulmonary function test; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s.